Copyright
©The Author(s) 2024.
World J Nephrol. Sep 25, 2024; 13(3): 96574
Published online Sep 25, 2024. doi: 10.5527/wjn.v13.i3.96574
Published online Sep 25, 2024. doi: 10.5527/wjn.v13.i3.96574
Pharmaceutical treatment | Potential nephrotoxic effects |
Sulfasalazine | Tubulointerstitial nephritis, gloermurlonephritis |
CsA | Nephritis, interstitial fibrosis |
TNFα Inhibitors | Glomerulonephritis |
Methotrexate | None at conventional doses |
Azathioprine | No direct evidence of a renal effect |
Corticosteroids | None |
Antibiotics (e.g., ciprofloxacin) | Acute kidney injury |
Vedolizumab | Acute interstitial nephritis |
Tofacitinib | Acute kidney injury |
Filgotinib | Increased drug concentration in renal impairment |
- Citation: Singh A, Khanna T, Mahendru D, Kahlon J, Kumar V, Sohal A, Yang J. Insights into renal and urological complications of inflammatory bowel disease. World J Nephrol 2024; 13(3): 96574
- URL: https://www.wjgnet.com/2220-6124/full/v13/i3/96574.htm
- DOI: https://dx.doi.org/10.5527/wjn.v13.i3.96574